Throughout the 14th Five-Year Plan period, China has significantly strengthened drug safety supervision, fully embraced the high-quality development of its pharmaceutical industry, and prioritized addressing the medication needs of its people. Currently, China's pharmaceutical industry stands as the second-largest in the world in terms of scale, with approximately 30% of global innovative drugs under research originating from the country. Since the inception of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market release, thereby effectively catering to the medication demands of key patient populations.
